PIP Search Page

Displaying 81 - 100 of 107

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Date Published Sort ascending
MHRA-100190-PIP01-21	Ordesekimab	Treatment of coeliac disease		Gastroenterology-Hepatology Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100122-PIP01-21	olpasiran	Prevention of cardiovascular events		Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100316-PIP01-21	latozinemab	Treatment of clinically symptomatic or pre-symptomatic frontotemporal dementia (FTD)		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100396-PIP01-21	sugemalimab	Treatment of non-small cell lung cancer (NSCLC)		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100199-PIP01-21	efgartigimod alfa	Treatment of Pemphigus		Dermatology	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100301-PIP01-21	Anti-neonatal Fc receptor human monoclonal antibody(Nipocalimab )	Treatment of chronic inflammatory demyelinating polyradiculoneuropathy		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100309-PIP01-21	gantenerumab	Prevention of Alzheimer's disease	Not available at present	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100206-PIP01-21	EMPAGLIFLOZIN	Treatment of ischaemic heart disease	Jardiance Jardiance	Endocrinology-Gynaecology-Fertility-metabolism	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100194-PIP01-21	sivopixant	Treatment of unexplained or refractory chronic cough		Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100204-PIP01-21	verdiperstat	Treatment of Amyotrophic lateral sclerosis	Dazluma	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100184-PIP01-21	BENRALIZUMAB	Non-cystic fibrosis bronchiectasis with an eosinophilic phenotype	FASENRA FASENRA FASENRA FASENRA FASENRA FASENRA	Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100135-PIP01-21	anti-CD40L humanized monoclonal antibody (SAR441344)	Treatment of Sjogren's Syndrome		Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100368-PIP01-21	aumolertinib	Treatment of lung cancer	Ameile	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100279-PIP01-21	Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide	Diabetic retinopathy		Ophthamology	W: decision granting a waiver in all age groups for the listed condition(s).	No	04/05/2022
MHRA-100163-PIP01-21	Vupanorsen (PF-07285557)	Treatment of Hypertriglyceridemia Prevention of cardiovascular events	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100155-PIP01-21	efgartigimod alfa	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100107-PIP01-21	1-(3-methylbutanoyl)-l-aspartyl-l-threonyl-l-histidyl-l-phenylalanyl-l-prolyl-(l-cystinyl-l-isoleucyl-[(n6-(s)-4-carboxy-4-palmitamidobutanoyl)-l-lysinyl]-l-phenylalanyl-l-glutamyl-l-prolyl-l-arginyl-l-serinyl-l-lysinyl-l-glycinyl-l-cystinyl)-l-lysinamide, disulfide, acetate	Treatment of polycythaemia vera		Haematology-Hemostaseology	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100112-PIP01-21	savolitinib	Treatment of renal neoplasms	Not available	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100080-PIP01-21	Anti-C1s Humanized IgG4 Monoclonal Antibody	Treatment of Immune Thrombocytopenic Purpura		Neurology Immunology -Rheumatology-Transplantation Haematology-Hemostaseology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100142-PIP01-21	Synthetic Hypericin	Treatment of cutaneous T-cell lymphoma	HyBryte	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021

Download XLSX

Search Filters: